HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

W Evan Secor Selected Research

Trichomonas Infections

1/2022Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.
11/2020A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis.
11/2019Trichomonas vaginalis Virus Among Women With Trichomoniasis and Associations With Demographics, Clinical Outcomes, and Metronidazole Resistance.
12/2015A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.
9/2013Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates.
10/2011Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure.
9/2010Mycoplasma hominis infection of Trichomonas vaginalis is not associated with metronidazole-resistant trichomoniasis in clinical isolates from the United States.
4/2008Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity.
4/2003In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


W Evan Secor Research Topics

Disease

38Infections
01/2022 - 09/2004
31Schistosomiasis (Bilharziasis)
11/2021 - 04/2007
10Schistosomiasis mansoni
01/2020 - 10/2007
9Trichomonas Infections
01/2022 - 04/2003
6Reinfection
08/2010 - 08/2002
5Persistent Infection
01/2022 - 10/2007
4Visceral Leishmaniasis (Kala Azar)
05/2007 - 05/2005
3Parasitic Diseases (Parasitic Disease)
07/2014 - 01/2013
2Hypersensitivity (Allergy)
09/2013 - 04/2008
2Malaria
03/2013 - 11/2012
1Gonorrhea
11/2019
1Dermatitis
06/2015
1Inflammation (Inflammations)
11/2012
1Parasitemia
11/2012
1Anemia
11/2012
1Sexually Transmitted Diseases (Sexually Transmitted Disease)
08/2011
1Disease Progression
10/2007
1Virus Diseases (Viral Diseases)
10/2007
1Eosinophilia
04/2007
1Coinfection
11/2005
1Pain (Aches)
04/2002

Drug/Important Bio-Agent (IBA)

17Praziquantel (Biltricide)FDA Link
01/2020 - 08/2002
16AntigensIBA
11/2021 - 09/2004
8Metronidazole (Metric)FDA LinkGeneric
01/2022 - 04/2008
4TinidazoleFDA Link
11/2020 - 04/2003
4NitroimidazolesIBA
12/2015 - 04/2008
4Immunoglobulin E (IgE)IBA
08/2010 - 01/2009
4CytokinesIBA
01/2009 - 11/2005
3Nucleic AcidsIBA
01/2022 - 08/2011
3VaccinesIBA
01/2016 - 03/2013
3Anti-Bacterial Agents (Antibiotics)IBA
12/2015 - 09/2010
3Pharmaceutical PreparationsIBA
03/2013 - 05/2009
24-nitroimidazoleIBA
11/2020 - 09/2013
2Interleukin-10 (Interleukin 10)IBA
01/2018 - 05/2006
2Polysaccharides (Glycans)IBA
01/2016 - 07/2014
2Immunoglobulin G (IgG)IBA
07/2014 - 01/2009
2Peptides (Polypeptides)IBA
03/2013 - 05/2009
2Interleukin-13IBA
01/2009 - 11/2007
2Interleukin-4 (Interleukin 4)IBA
01/2009 - 04/2007
2Interleukin-12 (IL 12)IBA
09/2007 - 05/2006
2leishmaninIBA
05/2007 - 10/2006
1SmokeIBA
11/2019
1DNA (Deoxyribonucleic Acid)IBA
01/2018
1AntibodiesIBA
01/2016
1Indicators and Reagents (Reagents)IBA
01/2016
1Ribosomal DNA (rDNA)IBA
06/2015
1LectinsIBA
01/2015
1GlycopeptidesIBA
07/2014
1FucoseIBA
07/2014
1Xylose (D-Xylose)FDA Link
07/2014
1EpitopesIBA
07/2014
1Drinking WaterIBA
04/2014
1cobamamide (adenosylcobalamin)IBA
09/2013
1nithiamideIBA
09/2013
1Disulfiram (Antabuse)FDA Link
09/2013
1Albendazole (Albenza)FDA Link
09/2013
1Ferritins (Ferritin)IBA
11/2012
1Antimalarials (Antimalarial Agents)IBA
11/2012
1Biomarkers (Surrogate Marker)IBA
03/2012
1Proteins (Proteins, Gene)FDA Link
03/2012
1CarbonIBA
01/2011
1SandIBA
03/2010
1Omalizumab (Xolair)FDA Link
05/2009
1IgE Receptors (Fc epsilon RI)IBA
01/2009
1Aligeron (AS 2)IBA
04/2008
1Immunodominant EpitopesIBA
09/2007
1Vitamin A (Retinol)FDA LinkGeneric
05/2007
1ZincIBA
05/2007
1Messenger RNA (mRNA)IBA
04/2007
1Interleukin-8 (Interleukin 8)IBA
05/2006
1InsecticidesIBA
05/2005
1ImmunosorbentsIBA
09/2004
1EnzymesIBA
09/2004
1Opiate AlkaloidsIBA
04/2002

Therapy/Procedure

14Mass Drug Administration
01/2021 - 12/2012
8Drug Therapy (Chemotherapy)
07/2021 - 01/2013
4Therapeutics
01/2022 - 10/2011
3Aftercare (After-Treatment)
01/2022 - 01/2009
1Highly Active Antiretroviral Therapy (HAART)
10/2007
1Bathroom Equipment
05/2005